JPRN-UMIN000015565
Recruiting
Phase 2
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer - Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer
ConditionsRefractory small-cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Refractory small-cell lung cancer
- Sponsor
- Dokkyo Medical University
- Enrollment
- 22
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Symptomatic brain metastasis 2\) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy 3\) With active double cancer or multicentric cancer 4\) Treated with radiotherapy within the past four weeks. 5\) With clinically important complications. 6\) With pleural effusion or pericardial effusion accumulates which need drainage 7\) With the history of hypersensitivity for nab\-paclitaxel, CBDCA 8\) Main organs had a serious medical risk factor, and the physicians judged treatment not to be safe. 9\) Physician concludes that the patient's participation in this trial is inappropriate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II study of nab-paclitaxel in patients with previously treated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012114Osaka City General Hospital30
Not yet recruiting
Not Applicable
Phase II study of nab-paclitaxel combined with S-1 in patients with early breast cancer:A multicenter clinical trialearly breast cancerJPRN-UMIN000027216The University of Tokushima Graduate School80
Completed
Not Applicable
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
Completed
Phase 2
Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer.on-small-cell lung cancerJPRN-UMIN000018233Shimane university hospital45
Recruiting
Phase 2
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35